Janney Montgomery Scott LLC Cuts Holdings in TransMedics Group, Inc. $TMDX

Janney Montgomery Scott LLC reduced its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 20.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,992 shares of the company’s stock after selling 1,807 shares during the quarter. Janney Montgomery Scott LLC’s holdings in TransMedics Group were worth $937,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Opal Wealth Advisors LLC purchased a new position in shares of TransMedics Group in the 2nd quarter worth $26,000. Smartleaf Asset Management LLC raised its position in TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after purchasing an additional 135 shares during the period. Quarry LP raised its position in TransMedics Group by 88.5% in the first quarter. Quarry LP now owns 592 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period. Sound Income Strategies LLC purchased a new position in TransMedics Group in the second quarter valued at about $48,000. Finally, Hager Investment Management Services LLC raised its position in TransMedics Group by 38.3% in the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company’s stock valued at $50,000 after purchasing an additional 205 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. Jefferies Financial Group assumed coverage on TransMedics Group in a research report on Monday. They issued a “buy” rating and a $145.00 price objective on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $142.00 price objective on shares of TransMedics Group in a research report on Tuesday. Oppenheimer raised their price objective on TransMedics Group from $130.00 to $150.00 and gave the company an “outperform” rating in a research report on Tuesday, June 17th. Zacks Research lowered TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Monday, August 25th. Seven equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $127.18.

TransMedics Group Stock Down 0.4%

NASDAQ:TMDX opened at $111.23 on Wednesday. The company has a market capitalization of $3.79 billion, a price-to-earnings ratio of 57.63 and a beta of 2.08. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $145.50. The stock has a 50-day simple moving average of $116.59 and a 200 day simple moving average of $112.69. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. The business had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period last year, the firm earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Sell-side analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.